OTC Equity - Dr. Scott L. Friedman: “Galectin Therapeutics, Inc. (NASDAQ: GALT) Spikes on Positive Data from Cirrhosis Study”

 – April 29, 2013 /Press Release/  –– 

Following the release of positive data involving their drugs GR-MD-02 and GM-CT-01 that are intended to inhibit galectin proteins as a means of treating liver fibrosis, shares of Galectin Therapeutics, Inc. (NASDAQ: GALT) spiked to a 52-week high of 5.22 during trading on Monday and while they have dipped down to a current mark of 4.98 they remain well above their 50-day moving average of 3.73 and their 200-day moving average of 2.55. The data was generated by the laboratory of Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai and showed that the drugs were able to able to reverse the most advanced stage of liver fibrosis, cirrhosis, in experimental animals given toxin-induced cirrhosis. Learn more